Vaccine adjuvants market is growing at a significant CAGR owing to increase in the prevalence of infectious diseases in humans, livestock & companion animals around the globe. Growing need for enhancing immune response and limited immunogenicity of novel vaccines expected to fuel the vaccine adjuvants market. Vaccine adjuvants are the substances added to the vaccines for enhancing the vaccine ability to protect against the infection. Vaccine adjuvants improve the immunogenicity of purified antigens, which has immunostimulatory capabilities and has been used in the vaccines for more than 90 years. Nowadays, a very less number of vaccine adjuvants are available such as MF 59 and aluminium salts. Vaccines are combined with the adjuvants to ensure body produces an efficient immune response to protect the person against the infection. Acquisitions and mergers, collaborations, and novel adjuvant introductions are the strategies applied by the market players to dominate the vaccine adjuvants market. For instance, in August 2013, FDA approved the Sequirus’s Afluria quadrivalent vaccine for people with 18 years or older. Similarly, funding by the government organizations to augment adjuvants research is anticipated to boost the vaccine adjuvants market. For instance, in April 2016, National Institute of Allergy and Infectious Diseases awarded 6 grants to various organizations including universities such as University of Wisconsin about US$ 3.1 Mn grants for vaccine adjuvants research.


Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX